Tauvid
- Generic Name: flortaucipir f 1 injection, for intravenous use
- Brand Name: Tauvid
- Drug Class: How Do Diagnosing Imaging Agents Work?
Tauvid (Flortaucipir F 1 Injection, for Intravenous Use) side effects drug center
- Related Drugs
- headache,
- injection site pain, and
- increased blood pressure
What Is Tauvid?
Tauvid (flortaucipir F 18 injection) is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease.
What Are Side Effects of Tauvid?
Side effects of Tauvid may include:
Dosage for Tauvid
The recommended dose of Tauvid is 370 MBq (10 mCi), administered as a bolus intravenous injection.
Tauvid In Children
The safety and effectiveness of Tauvid in pediatric patients have not been established.
What Drugs, Substances, or Supplements Interact with Tauvid?
Tauvid may interact with other medicines.
Tell your doctor all medications and supplements you use.
Tauvid During Pregnancy and Breastfeeding
Tell your doctor if you are pregnant or plan to become pregnant before using Tauvid; all radiopharmaceuticals, including Tauvid, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of radiation dose. It is unknown if Tauvid passes into breast milk. Breastfeeding women are advised to avoid breastfeeding for 4 hours after Tauvid administration.
Additional Information
Our Tauvid (flortaucipir F 18 injection), for Intravenous Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
SIDE EFFECTS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In clinical studies, 1921 study participants were exposed to TAUVID [see Clinical Studies]. In these studies, 1192 study participants received 240 MBq of TAUVID (about 65% of the recommended dose) and 729 study participants received 370 MBq of TAUVID (the recommended dose). The adverse reactions reported in greater than 0.5% within the studies are shown in Table 2.
Table 2: Adverse Reactions with a Frequency ≥0.5% in Adults Who Received TAUVID in Clinical Trials (n = 1921)
| Adverse Reaction | n (%) |
| Headache | 26 (1.4%) |
| Injection site pain | 23 (1.2%) |
| Increased blood pressure | 15 (0.8%) |
Read the entire FDA prescribing information for Tauvid (Flortaucipir F 1 Injection, for Intravenous Use)
© Tauvid Patient Information is supplied by Cerner Multum, Inc. and Tauvid Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.